Atu 027

Drug Profile

Atu 027

Alternative Names: Atu027

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Atugen AG
  • Developer Silence Therapeutics; Silence Therapeutics AG
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Protein kinase N3 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Head and neck cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Germany (IV, Infusion)
  • 13 Apr 2017 Atu 027 is available for licensing as of 28 Mar 2017.
  • 05 Jan 2016 Silence Therapeutics completes a phase I/II trial in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease) in Germany (EudraCT2012-004429-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top